Updated Nov. 19, 2013 at 4:09 p.m.

Premium Lock Payday for Pozen as Horizon acquires U.S. rights to pain drug Vimovo

Published: 2013-11-19 15:35:00
Updated: 2013-11-19 16:09:44

Chairman, CEO John Plachetka Chairman, CEO John Plachetka Image 1 of 2 · Next Image…

With a sales force already dedicated to selling an osteoarthritis drug, Horizon Pharma is better suited to selling Pozen's pain drug Vimovo. Read more about how Pozen benefits from the deal....

Read More
Read More

WRAL TechWire any time: Twitter, Facebook

Copyright 2014 WRAL TechWire. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Best of TechWire Insider

Techwire Inside Partners

OUR INSIDERS

Vivek Wadhwa
Commentary
Frank Vinluan
Life science
Dr. Mike Walden
Tech economy
Scroll